Visceral pain treatment market Size, Share, Growth, and Industry Analysis, By Type (HS-665, CC-8464, BLU-5937, APD-371, and others), By Application (In-patient and Out-patient), and Regional Forecast From 2025 To 2033

• 

   Request a Free Sample To Get More Information on this Market

VISCERAL PAIN TREATMENT MARKET REPORT OVERVIEW

The global visceral pain treatment market size was USD 14.21 billion in 2024 &, the market is expected to reach USD 22.37 billion by 2033, exhibiting a CAGR of 5.2% during the forecast period.

The global COVID-19 pandemic has been unprecedented and staggering, with the visceral pain treatment market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

Visceral pain is pain that originates from the organs within the abdominal, thoracic, or pelvic cavity. It can be caused by various medical conditions such as irritable bowel syndrome, pancreatitis, inflammatory bowel disease, endometriosis, and bladder disorders. Visceral pain can be challenging to diagnose and treat because it does not have a clear location and can be associated with other symptoms such as nausea, vomiting, and changes in bowel movements. The treatment of visceral pain depends on the underlying cause of the pain. In some cases, the pain can be managed with medications, while in other cases, more invasive procedures may be required.

One of the most common treatments for visceral pain is medication. Depending on the underlying cause of the pain, a range of medications may be used, including pain relievers, anti-inflammatory drugs, and antispasmodics. In some cases, antidepressants or antianxiety medications may be used to manage the associated symptoms of visceral pain..

COVID-19 IMPACT

"Pandemic Decreased the Market Demand"

The COVID-19 pandemic has had a significant impact on the healthcare industry, including the visceral pain treatment market. Visceral pain refers to the pain that arises from the internal organs, such as the stomach, liver, or pancreas, and can be caused by various medical conditions. The pandemic has led to a shift in healthcare priorities, with resources and attention being diverted towards managing and treating COVID-19 patients. This has resulted in a decline in the diagnosis and treatment of non-COVID-19 related conditions, including visceral pain. Moreover, restrictions on non-essential medical procedures and surgeries, as well as the fear of contracting the virus in healthcare settings, have resulted in a decrease in patient visits to healthcare facilities. This has led to a decline in demand for visceral pain treatments and a reduction in the revenues of companies operating in this market.

LATEST TRENDS

"Growing use of digital health solutions is expected to fuel the growth in the market"

Digital health solutions are becoming increasingly popular in the treatment of visceral pain. These solutions offer several advantages, such as greater accessibility, convenience, and cost-effectiveness, and can improve patient outcomes. Telemedicine, for instance, enables patients to receive remote consultations with healthcare providers, which can reduce the need for in-person visits and make it easier for patients to access care. This is particularly useful for patients who live in rural or remote areas, or those who have mobility issues. Mobile health apps can also be used to manage and monitor visceral pain. These apps enable patients to track their symptoms, medication use, and other health-related data, and provide real-time feedback to healthcare providers. This can help to improve patient adherence to treatment plans, and enable healthcare providers to make more informed decisions about patient care. Overall, the use of digital health solutions in the treatment of visceral pain is expected to continue to grow, as patients and healthcare providers increasingly embrace the benefits of these technologies.

VISCERAL PAIN TREATMENT MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented HS-665, CC-8464, BLU-5937, APD-371 and others.

By Application Analysis

Based on application, the market can be divided into In-patient and Out-patient.

DRIVING FACTORS

"Increasing prevalence of gastrointestinal disorders to foster the market growth"

Gastrointestinal disorders are becoming more prevalent globally, with conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD) affecting millions of people worldwide. These conditions often cause visceral pain, which can have a significant impact on patients' quality of life. The rising prevalence of these disorders is driving the demand for effective treatments to manage visceral pain. IBD, for example, is a chronic inflammatory condition of the gastrointestinal tract that affects an estimated 3 million people in the United States alone. GERD is a condition where stomach acid flows back into the oesophagus, causing heartburn and other symptoms. These conditions can cause severe and chronic visceral pain, which can be difficult to manage and can significantly impact patients' quality of life leading to an increase in the visceral pain treatment market share.

"Growing geriatric population to result in the expansion of the market"

As the global population ages, the prevalence of chronic conditions that cause visceral pain is increasing. The elderly population is more susceptible to developing conditions such as osteoarthritis, cancer, and diabetes, which can cause visceral pain. Chronic pain in the elderly is a major healthcare challenge, and effective treatment options are essential to manage their pain and improve their quality of life. In addition, the elderly population often has complex medical needs and may be taking multiple medications, which can increase their risk of adverse drug reactions and interactions. This highlights the need for personalized and safe treatments for visceral pain in the elderly population.

RESTRAINING FACTORS

"Side effects of medications to hamper the market growth"

Many medications used to treat visceral pain can have side effects, which can impact patients' quality of life and limit their use of the medication. Opioid medications, for example, are effective at managing pain but can cause constipation, nausea, drowsiness, confusion, and addiction. Long-term use of opioids can also lead to tolerance, meaning patients need higher doses to achieve the same pain relief. This can increase the risk of overdose and other serious side effects These side effects can impact patients' quality of life and limit their use of the medication, and highlight the need for safer and more effective visceral pain treatment.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

VISCERAL PAIN TREATMENT MARKET REGIONAL INSIGHTS

"North America to lead the market owing to the increasing prevalence of visceral pain disorders."

The North American region is expected to contribute the most in the visceral pain treatment market growth. This can be attributed to several factors, including the increasing prevalence of visceral pain disorders, rising healthcare expenditure, and the presence of major market players in the region. In addition, the region has a well-established healthcare infrastructure and regulatory framework, which supports the development and adoption of new treatments.

KEY INDUSTRY PLAYERS

"Key players are employing advanced technologies in order to stimulate further growth of the market. "

All the major players are motivated to offer superior and more advanced services in order to gain a competitive edge in the market. To increase their market presence, vendors are using a variety of techniques, including product launches, regional growth, strategic alliances, partnerships, mergers, and acquisitions.

List of Top Visceral pain treatment Companies

• Addex Therapeutics Ltd: Geneva, Switzerland
• Astellas Pharma Inc.: Tokyo, Japan
• Chromocell Corporation: North Brunswick, New Jersey, USA
• GIcare Pharma Inc.: Seoul, South Korea
• Grunenthal GmbH: Aachen, Germany
• Medestea Research & Production S.p.A.: Torino, Italy
• Neurim Pharmaceuticals Ltd: Tel Aviv, Israel
• Pfizer Inc.: New York City, New York, USA

REPORT COVERAGE

This report examines an understanding of the visceral pain treatment market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.